1. Guidance updated 8/27/25. CooperCompanies Fiscal 2025 & Q4'25 financial guidance | | | | FY25 Guidance | Q4 2025 Guidance | | --- | --- | --- | --- | --- | | | Total | $4,076 - | $4,096 | $1,049 - $1,069 | | | | (4% - | 4.5% organic growth) | (2% - 4% organic growth) | | s e al S | CooperVision | $2,734 - | $2,747 | $700 - $713 | | | | (4% - | 5% organic growth) | (2% - 4% organic growth) | | | CooperSurgical | $1,343 - | $1,349 | $350 - $356 | | | | (3% - | 3.5% organic growth) | (2% - 4% organic growth ...

[Press Release Overview](index=1&type=section&id=PRESS%20RELEASE) This section provides an executive summary of CooperCompanies' fiscal year 2025 third-quarter performance and updated financial outlook [CEO Commentary](index=1&type=section&id=CEO%20Commentary) CooperCompanies CEO Al White highlighted strong margins, double-digit earnings growth, and robust free cash flow in Q3 FY2025, despite lower-than-expected revenue, while raising earnings guidance - The company achieved **strong margins**, **double-digit earnings growth**, and **robust free cash flow**, reflecting operational excellence as a core growth strategy[2](index=2&type=chunk) - Despite lower-than-expected revenue, the company **raised its earnings guidance** based on operational performance and anticipates MyDay® products will drive revenue improvement in Q4 and FY2026[2](index=2&type=chunk) [Fiscal Year 2025 Third Quarter Operating Results](index=1&type=section&id=Third%20Quarter%20Operating%20Results) This section details CooperCompanies' consolidated financial performance, including revenue, earnings, and segment-specific results for CooperVision and CooperSurgical [Consolidated Operating Highlights](index=1&type=section&id=Consolidated%20Operating%20Highlights) CooperCompanies reported $1,060.3 million in total revenue, a 6% increase, with GAAP diluted EPS decreasing by 6% and non-GAAP diluted EPS increasing by 15% Fiscal Year 2025 Third Quarter Key Financial Metrics | Metric | Q3 FY2025 (Millions USD) | Q3 FY2024 (Millions USD) | YoY Change | | :----- | :--- | :--- | :--------- | | Revenue | $1,060.3 | $1,002.8 | +6% | | GAAP Diluted EPS | $0.49 | $0.52 | -6% | | Non-GAAP Diluted EPS | $1.10 | $0.96 | +15% | | GAAP Gross Margin | 65% | 66% | -100 bps | | Non-GAAP Gross Margin | 67% | 66% | +70 bps | | GAAP Operating Margin | 17% | 19% | -200 bps | | Non-GAAP Operating Margin | 26% | 26% | +60 bps | - **GAAP gross margin decreased** primarily due to the CooperSurgical product line exit, while **non-GAAP gross margin increased** from ongoing efficiency gains, a favorable product mix, and positive foreign exchange impacts[5](index=5&type=chunk) - The **increase in non-GAAP operating margin** resulted from stronger gross margins and targeted expense leverage, partially offset by higher research and development expenses[6](index=6&type=chunk) [CooperVision (CVI) Fiscal Year 2025 Third Quarter Revenue](index=2&type=section&id=Third%20Quarter%20CooperVision%20(CVI)%20Revenue) CooperVision reported $718.4 million in revenue, a 6% increase, with strong performance in toric and multifocal lenses and significant growth in the EMEA region CVI Total Revenue Overview (Q3 FY2025) | Metric | Q3 FY2025 Revenue (Millions USD) | Reported YoY Change | Constant Currency YoY Change | Organic YoY Change | | :----- | :----------- | :------------------ | :--------------------------- | :----------------- | | CVI Total Revenue | $718.4 | +6% | +2% | +2% | [CVI Revenue by Product Category](index=2&type=section&id=CVI%20Revenue%20by%20Product%20Category) CVI's revenue by product category shows strong reported and organic growth in toric and multifocal lenses, while spherical lenses and other categories saw modest growth CVI Revenue by Product Category (Q3 FY2025) | Category | Q3 FY2025 Revenue (Millions USD) | Reported YoY Change | Organic YoY Change | | :------- | :----------- | :------------------ | :----------------- | | Toric and Multifocal | $358.8 | +10% | +6% | | Spherical and Other | $359.6 | +3% | -1% | [CVI Revenue by Geography](index=2&type=section&id=CVI%20Revenue%20by%20Geography) CVI's revenue by geography indicates strong reported growth in EMEA, with modest growth in the Americas and a slight decline in Asia Pacific on an organic basis CVI Revenue by Geography (Q3 FY2025) | Region | Q3 FY2025 Revenue (Millions USD) | Reported YoY Change | Organic YoY Change | | :-------- | :----------- | :------------------ | :----------------- | | Americas | $286.0 | +2% | +3% | | Europe, Middle East, and Africa (EMEA) | $292.1 | +14% | +6% | | Asia Pacific | $140.3 | +1% | -5% | [CooperSurgical (CSI) Fiscal Year 2025 Third Quarter Revenue](index=2&type=section&id=Third%20Quarter%20CooperSurgical%20(CSI)%20Revenue) CooperSurgical achieved $341.9 million in revenue, a 4% increase, driven by strong performance in the fertility business category CSI Total Revenue Overview (Q3 FY2025) | Metric | Q3 FY2025 Revenue (Millions USD) | Reported YoY Change | Constant Currency YoY Change | Organic YoY Change | | :----- | :----------- | :------------------ | :--------------------------- | :----------------- | | CSI Total Revenue | $341.9 | +4% | +4% | +2% | [CSI Revenue by Product Category](index=3&type=section&id=CSI%20Revenue%20by%20Product%20Category) CSI's revenue by product category shows stronger reported and organic growth in the fertility business compared to clinic and surgical categories CSI Revenue by Product Category (Q3 FY2025) | Category | Q3 FY2025 Revenue (Millions USD) | Reported YoY Change | Organic YoY Change | | :------- | :----------- | :------------------ | :----------------- | | Clinic and Surgical | $204.8 | +3% | +1% | | Fertility | $137.1 | +6% | +3% | [Other Financial Information](index=2&type=section&id=Other%20Financial%20Information) Interest expense decreased due to lower average rates and debt, while the company generated $164.6 million in free cash flow and repurchased $52.1 million of common stock Interest Expense and Free Cash Flow (Q3 FY2025) | Metric | Q3 FY2025 (Millions USD) | Q3 FY2024 (Millions USD) | YoY Change (Millions USD) | | :----- | :--- | :--- | :--------- | | GAAP Interest Expense | $25.4 | $28.5 | -$3.1 | | Non-GAAP Interest Expense | $24.7 | $27.1 | -$2.4 | | Cash Flow from Operations | $261.5 | N/A | N/A | | Capital Expenditures | $96.9 | N/A | N/A | | Free Cash Flow | $164.6 | N/A | N/A | - The company repurchased **$52.1 million of common stock**, approximately **724,300 shares** at an average price of **$71.97 per share**, with **$163.6 million remaining** under the existing share repurchase program[11](index=11&type=chunk) [Fiscal Year 2025 Financial Guidance Update](index=3&type=section&id=Fiscal%20Year%202025%20Financial%20Guidance) This section presents the updated non-GAAP financial guidance for CooperCompanies for both the fourth quarter and the full fiscal year 2025 [Fiscal Fourth Quarter 2025 Guidance](index=3&type=section&id=Fiscal%20Fourth%20Quarter%202025%20Guidance) The company updated its non-GAAP financial guidance for Q4 FY2025, projecting total revenue between $1,049 million and $1,069 million and non-GAAP diluted EPS between $1.10 and $1.14 Fiscal Fourth Quarter 2025 Financial Guidance | Metric | Q4 FY2025 Guidance (Millions USD) | Organic Growth | | :----- | :------------ | :------------- | | Total Revenue | $1,049 - $1,069 | 2% to 4% | | CVI Revenue | $700 - $713 | 2% to 4% | | CSI Revenue | $350 - $356 | 2% to 4% | | Non-GAAP Diluted EPS | $1.10 - $1.14 | N/A | [Fiscal Year 2025 Full Year Guidance](index=3&type=section&id=Fiscal%202025%20Full%20Year%20Guidance) The company updated its non-GAAP financial guidance for full-year FY2025, forecasting total revenue between $4,076 million and $4,096 million and non-GAAP diluted EPS between $4.08 and $4.12 Fiscal Year 2025 Full Year Financial Guidance | Metric | FY2025 Full Year Guidance (Millions USD) | Organic Growth | | :----- | :------------ | :------------- | | Total Revenue | $4,076 - $4,096 | 4% to 4.5% | | CVI Revenue | $2,734 - $2,747 | 4% to 5% | | CSI Revenue | $1,343 - $1,349 | 3% to 3.5% | | Non-GAAP Diluted EPS | $4.08 - $4.12 | N/A | [Reconciliation of Selected GAAP Results to Non-GAAP Results](index=4&type=section&id=Reconciliation%20of%20Selected%20GAAP%20Results%20to%20Non-GAAP%20Results) This section explains the company's non-GAAP financial measures and provides detailed reconciliation tables from GAAP to non-GAAP results [Non-GAAP Measures Explanation](index=4&type=section&id=Non-GAAP%20Measures%20Explanation) The company provides non-GAAP measures to offer investors a clearer understanding of consolidated operating performance, excluding costs not typically part of ongoing operations - Non-GAAP measures exclude costs not typically part of ongoing operations, such as **intangible asset amortization**, **acquisition and integration costs**, and **business exit expenses**[15](index=15&type=chunk) - Constant currency revenue growth adjusts for foreign exchange fluctuations, while organic revenue growth further excludes the impact of **acquisitions, divestitures, and discontinued operations**[16](index=16&type=chunk) - **Free cash flow**, defined as cash provided by operating activities less capital expenditures, is considered a useful metric for assessing liquidity and capital allocation[17](index=17&type=chunk) [GAAP to Non-GAAP Reconciliation Tables](index=5&type=section&id=GAAP%20to%20Non-GAAP%20Reconciliation%20Tables) Detailed reconciliation tables are provided for gross profit, operating profit, and earnings per share, outlining adjustments for the three and nine months ended July 31, 2025 and 2024 GAAP to Non-GAAP Gross Profit Reconciliation | Metric (Three Months Ended July 31) | 2025 (Millions USD) | 2025 Margin % | 2024 (Millions USD) | 2024 Margin % | | :------------------------------ | :-------------- | :------------ | :-------------- | :------------ | | GAAP Gross Profit | $692.0 | 65% | $663.0 | 66% | | Total Adjustments | $21.4 | 2% | $4.7 | 0% | | Non-GAAP Gross Profit | $713.4 | 67% | $667.7 | 66% | GAAP to Non-GAAP Operating Profit Reconciliation | Metric (Three Months Ended July 31) | 2025 (Millions USD) | 2025 Margin % | 2024 (Millions USD) | 2024 Margin % | | :------------------------------ | :-------------- | :------------ | :-------------- | :------------ | | GAAP Operating Profit | $175.7 | 17% | $192.5 | 19% | | Total Adjustments | $100.7 | 9% | $63.6 | 7% | | Non-GAAP Operating Profit | $276.4 | 26% | $256.1 | 26% | GAAP to Non-GAAP Net Income and EPS Reconciliation | Metric (Three Months Ended July 31) | 2025 (Millions USD) | 2025 EPS | 2024 (Millions USD) | 2024 EPS | | :------------------------------ | :-------------- | :------- | :-------------- | :------- | | GAAP Net Income | $98.3 | $0.49 | $104.7 | $0.52 | | Total Adjustments | $122.0 | $0.61 | $87.2 | $0.44 | | Non-GAAP Net Income | $220.3 | $1.10 | $191.9 | $0.96 | [Notes to Non-GAAP Adjustments](index=6&type=section&id=Notes%20to%20Non-GAAP%20Adjustments) This section details various expenses included in non-GAAP adjustments, such as acquisition and integration costs, business exit costs, EU MDR compliance, and business optimization expenses - Acquisition and integration-related expenses in FY2025 primarily relate to the **obp Surgical and Cook Medical acquisitions and integration expenditures**, including long-lived asset write-offs, facility rationalization, and redundant personnel costs[21](index=21&type=chunk) - Business exit costs in FY2025 include **$12.7 million in inventory write-offs** and **$14.3 million in write-offs of certain long-lived assets**[23](index=23&type=chunk) - Business optimization expenses in FY2025 include **$2.7 million in employee severance costs** aimed at improving organizational efficiency and optimizing the overall cost structure[25](index=25&type=chunk) [Constant Currency and Organic Revenue Growth Reconciliation](index=12&type=section&id=Constant%20Currency%20and%20Organic%20Revenue%20Growth%20Reconciliation) This reconciliation table illustrates the impact of foreign exchange fluctuations and acquisitions/divestitures on reported revenue growth for CooperVision, CooperSurgical, and total revenue in Q3 FY2025 Total Net Sales Reconciliation (Q3 FY2025) | Metric | Q3 FY2025 (Millions USD) | Reported Change % | FX Impact | Constant Currency Change % | Acquisitions and Divestitures | Organic Change % | | :----- | :-------------- | :---------------- | :-------------- | :------------------------- | :---------------------------- | :--------------- | | CooperVision | $718.4 | 6% | (4)% | 2% | —% | 2% | | CooperSurgical | $341.9 | 4% | —% | 4% | (2)% | 2% | | Total | $1,060.3 | 6% | (3)% | 3% | (1)% | 2% | [Corporate Information & Disclosures](index=6&type=section&id=Corporate%20Information%20%26%20Disclosures) This section includes details on investor communications, company background, forward-looking statements, and investor contact information [Audio Webcast and Conference Call](index=6&type=section&id=Audio%20Webcast%20and%20Conference%20Call) CooperCompanies held an audio webcast and conference call on August 27, 2025, at 5:00 PM ET to discuss its Q3 results, with a replay available on the investor relations website - An audio webcast and conference call was held on **August 27, 2025, at 5:00 PM ET** to discuss third-quarter results, with live and replay access available at **www.investor.coopercos.com**[29](index=29&type=chunk)[30](index=30&type=chunk) [About CooperCompanies](index=7&type=section&id=About%20CooperCompanies) CooperCompanies (Nasdaq: COO) is a leading global medical device company with two business units, CooperVision and CooperSurgical, operating in over 130 countries - CooperCompanies is a **leading global medical device company** with two business units: **CooperVision** (contact lenses) and **CooperSurgical** (fertility and women's healthcare)[31](index=31&type=chunk) - The company has **over 16,000 employees**, sells products in **more than 130 countries**, and positively impacts the lives of **over 50 million people annually**[31](index=31&type=chunk) [Forward-Looking Statements and Risk Factors](index=7&type=section&id=Forward-Looking%20Statements) This press release contains forward-looking statements regarding guidance, plans, and future performance, subject to various risks including economic conditions, international conflicts, and regulatory changes - Forward-looking statements are subject to various risks, including adverse changes in **global or regional business, political, and economic conditions**, the impact of **international conflicts**, and **fluctuations in foreign currency exchange and interest rates**[33](index=33&type=chunk)[34](index=34&type=chunk) - Other significant risks include adverse impacts related to **acquisitions**, costs and potential liabilities for **compliance with U.S. and foreign laws and healthcare regulations** (e.g., HIPAA, CCPA, GDPR, EU MDR), **disruptions in manufacturing or distribution facility operations**, **cybersecurity attacks**, and **new governmental laws and regulations**[34](index=34&type=chunk)[35](index=35&type=chunk) [Investor Contact Information](index=9&type=section&id=Contact%20Information) This section provides contact details for the investor relations department for inquiries - Investors may contact **Kim Duncan, Vice President, Investor Relations & Risk Management**, at **925-460-3663** or **ir@cooperco.com**[37](index=37&type=chunk) [Consolidated Financial Statements](index=10&type=section&id=Consolidated%20Financial%20Statements) This section presents the company's consolidated condensed balance sheets and statements of income for the specified periods [Consolidated Condensed Balance Sheets](index=10&type=section&id=Consolidated%20Condensed%20Balance%20Sheets) As of July 31, 2025, total assets were $12,376.7 million and total liabilities were $4,023.7 million, with increased cash and decreased long-term debt compared to October 31, 2024 Consolidated Condensed Balance Sheet Highlights | Metric | July 31, 2025 (Millions USD) | October 31, 2024 (Millions USD) | | :----- | :----------------------- | :-------------------------- | | Total Current Assets | $2,137.8 | $1,951.5 | | Total Assets | $12,376.7 | $12,315.2 | | Total Current Liabilities | $1,010.1 | $1,022.8 | | Total Liabilities | $4,023.7 | $4,231.6 | | Shareholders' Equity | $8,353.0 | $8,083.6 | - **Cash and cash equivalents increased from $107.6 million to $124.9 million**, with increases also noted in trade receivables and inventories[39](index=39&type=chunk) - **Long-term debt decreased from $2,550.4 million to $2,431.4 million**, contributing to a reduction in total liabilities[39](index=39&type=chunk) [Consolidated Statements of Income](index=11&type=section&id=Consolidated%20Statements%20of%20Income) For the three months ended July 31, 2025, net sales rose to $1,060.3 million, with net income of $98.3 million and diluted EPS of $0.49 Consolidated Statements of Income Highlights (Three Months Ended July 31) | Metric | 2025 (Millions USD) | 2024 (Millions USD) | YoY Change (Millions USD) | | :----- | :-------------- | :-------------- | :--------- | | Net Sales | $1,060.3 | $1,002.8 | +$57.5 | | Gross Profit | $692.0 | $663.0 | +$29.0 | | Operating Profit | $175.7 | $192.5 | -$16.8 | | Net Income | $98.3 | $104.7 | -$6.4 | | Diluted EPS | $0.49 | $0.52 | -$0.03 | Consolidated Statements of Income Highlights (Nine Months Ended July 31) | Metric | 2025 (Millions USD) | 2024 (Millions USD) | YoY Change (Millions USD) | | :----- | :-------------- | :-------------- | :--------- | | Net Sales | $3,027.3 | $2,877.0 | +$150.3 | | Gross Profit | $2,031.3 | $1,918.0 | +$113.3 | | Operating Profit | $542.5 | $507.3 | +$35.2 | | Net Income | $290.3 | $274.8 | +$15.5 | | Diluted EPS | $1.45 | $1.37 | +$0.08 |

SAN RAMON, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal third quarter ended July 31, 2025. Revenue increased 6% year-over-year to $1,060.3 million. CooperVision (CVI) revenue up 6% to $718.4 million, and CooperSurgical (CSI) revenue up 4% to $341.9 million.GAAP diluted earnings per share (EPS) of $0.49, down $0.03 or 6% from last year's third quarter.Non-GAAP diluted EPS of $1.10, up $0.14 o ...

Core Insights - The Cooper Companies (COO) is currently more attractive to value investors compared to Merit Medical (MMSI) based on various financial metrics and rankings [1][3][7] Valuation Metrics - COO has a forward P/E ratio of 18.10, while MMSI has a forward P/E of 24.27, indicating that COO is potentially undervalued [5] - The PEG ratio for COO is 1.79, compared to MMSI's PEG ratio of 2.39, suggesting that COO has a better balance between price and expected earnings growth [5] - COO's P/B ratio is 1.77, significantly lower than MMSI's P/B of 3.51, further supporting the argument that COO is more attractively valued [6] Rankings and Grades - COO holds a Zacks Rank of 2 (Buy), while MMSI has a Zacks Rank of 3 (Hold), indicating a stronger earnings outlook for COO [3] - The Value grade for COO is B, whereas MMSI has a Value grade of C, reflecting the superior valuation metrics of COO [6]

Group 1 - The Cooper Companies (COO) closed at $73.48, with a 0.8% gain over the past four weeks, and analysts set a mean price target of $92.93, indicating a 26.5% upside potential [1] - The mean estimate consists of 15 short-term price targets with a standard deviation of $7.52, where the lowest estimate is $76.00 (3.4% increase) and the highest is $105.00 (42.9% increase) [2] - Analysts show strong agreement on COO's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for COO has increased by 0.1% over the past month, with one estimate going higher and no negative revisions [12] - COO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of potential gains, it does provide a directional guide for price movement [14]

Key Takeaways COO Q3 revenues are likely to be $982M, up 5.4% y/y, with projected EPS growth of 8.2%.COO benefits from strong MyDay, Clarity, and Biofinity demand across global markets.COO's CSI faces fertility weakness, partly offset by minimally-invasive surgical and OVP Surgical growth.The Cooper Companies, Inc.’s (COO) third-quarter fiscal 2025 results are scheduled to be released on Aug. 27, after the closing bell.In the last reported quarter, the company’s earnings beat the Zacks Consensus Estimate by ...

Analysts on Wall Street project that The Cooper Companies (COO) will announce quarterly earnings of $1.06 per share in its forthcoming report, representing an increase of 10.4% year over year. Revenues are projected to reach $1.07 billion, increasing 6.2% from the same quarter last year. It is projected by analysts that the 'Revenue by Category- CSI- Office and surgical' will reach $209.17 million. The estimate indicates a change of +5.7% from the prior-year quarter. The collective assessment of analysts po ...

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for The Cooper Companies, driven by higher revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - The Cooper Companies is expected to report quarterly earnings of $1.06 per share, reflecting a +10.4% year-over-year change, with revenues projected at $1.07 billion, up 6.2% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model shows a positive Earnings ESP of +0.58% for The Cooper Companies, suggesting a likelihood of beating the consensus EPS estimate [12]. Historical Performance - The Cooper Companies has beaten consensus EPS estimates in three out of the last four quarters, with a recent surprise of +3.23% [13][14]. Additional Considerations - While an earnings beat may influence stock movement, other factors can also play a significant role in stock performance post-earnings release [15][17].

Core Insights - The Cooper Companies, Inc. (COO) is focusing on strategic investments in innovation and has a diversified product base that supports long-term growth, although it faces near-term macro and inventory challenges, particularly in fertility and global consumer spending [1] Financial Performance - COO's shares have declined by 20% this year, contrasting with a 2.3% decline in the industry and a 9.6% increase in the S&P 500 Index [2] - The company has a market capitalization of $14.65 billion and is projected to see a 10.1% improvement in its bottom line over the next five years, with earnings beating estimates in three of the last four quarters [2][3] Operational Highlights - COO achieved solid organic top-line growth with adjusted earnings per share (EPS) increasing by 14% year over year to 96 cents, and operating margin expanded to 24.9% due to efficiency gains and disciplined cost management [4][8] - The MyDay daily silicone hydrogel lenses and MySight myopia management products have shown significant growth, with increases of 10% and 35% year over year, respectively [5][8] - The surgical portfolio, particularly CooperSurgical, reported an 8% revenue growth, with office-based surgical devices and PARAGARD IUDs growing by 13% and 18%, respectively [6][9] Challenges - Fertility revenue growth has slowed to 3%, attributed to declining cycles in Asia and deferred spending by clinics, leading management to revise growth expectations for the fertility segment to low-single-digit growth for fiscal 2025 [10] - The company is facing inventory and channel destocking pressures, which are impacting revenue visibility despite strong underlying demand [11] - COO anticipates a $4 million tariff impact on fiscal 2025 cost of goods sold (COGS) and a 3% EPS headwind in fiscal 2026 due to potential tariff and foreign exchange risks [12] Revenue Estimates - The Zacks Consensus Estimate for fiscal 2025 revenues is $4.12 billion, indicating a growth of 5.7% from the previous year, with adjusted EPS expected to improve by 10% to $4.06 [13]

Company Overview - CooperCompanies is a leading global medical device company with a focus on enhancing people's experiences through its two business units: CooperVision and CooperSurgical [2] - CooperVision is a prominent player in the contact lens industry, while CooperSurgical specializes in fertility and women's healthcare [2] - The company is headquartered in San Ramon, California, employs over 16,000 people, and sells products in more than 130 countries, positively impacting over 50 million lives annually [2] Upcoming Events - CooperCompanies will participate in the Wells Fargo Healthcare Conference on September 3, 2025, with President and CEO Al White representing the company [1] - The session is scheduled for 3:00 PM ET, and a webcast will be available for investors and interested parties [1]